Discounted Cash Flow (DCF) Analysis Levered
Blueprint Medicines Corporation (BPMC)
$86.82
-3.68 (-4.07%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Actual | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected | 2028 Projected |
Revenue | 66.51 | 793.73 | 180.08 | 204.04 | 249.38 | 904.99 | 3,284.18 | 11,918.16 | 43,250.58 | 156,954.75 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | -278.01 | 387.03 | -298.65 | -502.28 | -436.85 | -1,731.10 | -6,282.11 | -22,797.53 | -82,731.40 | -300,229.21 |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | -14.01 | -3.16 | -261.24 | -8.92 | -16.06 | -321 | -1,164.88 | -4,227.32 | -15,340.79 | -55,671.17 |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | -292.03 | 383.88 | -559.89 | -511.20 | -452.91 | -2,052.10 | -7,446.99 | -27,024.85 | -98,072.19 | -355,900.39 |
Weighted Average Cost Of Capital
Share price | $ 86.82 |
---|---|
Beta | 0.633 |
Diluted Shares Outstanding | 60.56 |
Cost of Debt | |
Tax Rate | -0.19 |
After-tax Cost of Debt | 6.67% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 7.344 |
Total Debt | 774.12 |
Total Equity | 5,257.65 |
Total Capital | 6,031.77 |
Debt Weighting | 12.83 |
Equity Weighting | 87.17 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Actual | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected | 2028 Projected |
Revenue | 66.51 | 793.73 | 180.08 | 204.04 | 249.38 | 904.99 | 3,284.18 | 11,918.16 | 43,250.58 | 156,954.75 |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | -278.01 | 387.03 | -298.65 | -502.28 | -436.85 | -1,731.10 | -6,282.11 | -22,797.53 | -82,731.40 | -300,229.21 |
Capital Expenditure | -14.01 | -3.16 | -261.24 | -8.92 | -16.06 | -321 | -1,164.88 | -4,227.32 | -15,340.79 | -55,671.17 |
Free Cash Flow | -292.03 | 383.88 | -559.89 | -511.20 | -452.91 | -2,052.10 | -7,446.99 | -27,024.85 | -98,072.19 | -355,900.39 |
WACC | ||||||||||
PV LFCF | -1,913.20 | -6,472.99 | -21,900.29 | -74,095.99 | -250,691.44 | |||||
SUM PV LFCF | -355,073.92 |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 7.26 |
Free cash flow (t + 1) | -363,018.40 |
Terminal Value | -6,901,490.42 |
Present Value of Terminal Value | -4,861,316.83 |
Intrinsic Value
Enterprise Value | -5,216,390.74 |
---|---|
Net Debt | 702.84 |
Equity Value | -5,217,093.58 |
Shares Outstanding | 60.56 |
Equity Value Per Share | -86,150.36 |